Converted by EDGARwiz

0001551163-17-000107.txt : 20170518 0001551163-17-000107.hdr.sgml : 20170518 20170517181437 ACCESSION NUMBER: 0001551163-17-000107 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 27 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170518 DATE AS OF CHANGE: 20170517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOETHICS LTD CENTRAL INDEX KEY: 0000894560 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 870485312 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 033-55254-41 FILM NUMBER: 17853007 BUSINESS ADDRESS: STREET 1: 1661 LAKEVIEW CIRCLE CITY: OGDEN STATE: UT ZIP: 84403 BUSINESS PHONE: (801) 399-3632 MAIL ADDRESS: STREET 1: 1661 LAKEVIEW CIRCLE CITY: OGDEN STATE: UT ZIP: 84403 10-Q 1 f20170331bioethics10qv6vedga.htm Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 5(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ______________________________ to ______________________________

Commission File Number 33-55254-41


BIOETHICS, LTD.
(Exact name of registrant as specified in charter)

NEVADA	87-0485312
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1661 Lakeview Circle, Ogden, Utah	84403
(Address of principal executive offices)	(Zip Code)

(801) 399-3632
(Issuer’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

[ ]

Accelerated filer

[ ]

Non-accelerated filer

[ ]

Smaller reporting company

[X]

Emerging growth company

[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes [X] No [ ]

As of May 15, 2017, the issuer had outstanding 116,000,000 shares of common stock, par value $0.001.

BIOETHICS, LTD.

FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2017

INDEX

PART I Financial Information

Item 1.

Financial Statements (Unaudited)

Item 2. Management’s Discussion and Analysis of Financial Condition

and Results of Operations

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 4. Controls and Procedures

PART II Other Information

Item 1. Legal Proceedings

Item 1A. Risk Factors

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 3. Defaults Upon Senior Securities

Item 4. Mine Safety Disclosures

Item 5. Other Information

Item 6. Exhibits

SIGNATURES

PART I – FINANCIAL INFORMATION

BIOETHICS, LTD.

CONTENTS

PAGE

Unaudited Balance Sheets,

March 31, 2017 and December 31, 2016

Unaudited Statements of Operations,

For the three months ending March 31, 2017 and 2016

Unaudited Statements of Cash Flows,

For the three months ended March 31, 2017 and 2016

Notes to Unaudited Financial Statements for the three months

ended March 31, 2017 and 2016


BIOETHICS, LTD.
Balance Sheets
(Unaudited)

ASSETS
			March 31,	December 31,
			2017	2016

CURRENT ASSETS

	Cash and cash equivalents		$ 51,684	$ 65,900
	Prepaid expenses		4,500	-

		Total Current Assets	56,184	65,900

FIXED ASSETS, NET			1,298	1,369

		TOTAL ASSETS	$ 57,482	$ 67,269

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES

	Accounts payable		$ 3,436	$ 6,191
	Accrued interest - related party		6,000	5,250
	Accrued interest		19,046	15,890
	Notes payable		35,000	35,000
	Notes payable - related party		25,000	25,000
	Convertible notes payable		100,000	100,000

		Total Current Liabilities	188,482	187,331

		TOTAL LIABILITIES	188,482	187,331

STOCKHOLDERS' EQUITY (DEFICIT)

	Preferred stock, $0.01 par value; 25,000,000 shares
	authorized, -0- shares issued and outstanding		-	-
	Common stock, $0.001 par value; 150,000,000 shares
	authorized, 116,000,000 shares issued and outstanding		116,000	116,000
	Additional paid-in capital		385,414	385,414
	Accumulated deficit		(632,414)	(621,476)

		Total Stockholders' Equity (Deficit)	(131,000)	(120,062)

		TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 57,482	$ 67,269

The accompanying notes are an integral part of these unaudited financial statements.


BIOETHICS, LTD.
Statements of Operations
(Unaudited)

			For the Three Months Ended
			March 31,
			2017	2016


NET REVENUES			$ -	$ -

OPERATING EXPENSES

	General and administrative		7,032	9,449

		Total Operating Expenses	7,032	9,449

LOSS FROM OPERATIONS			(7,032)	(9,449)

OTHER INCOME (EXPENSES)

	Interest income		-	1,858
	Interest expense (including amortization of debt discount
	of $-0- and $25,000, respectively)		(3,906)	(28,216)

		Total Other Income (Expenses)	(3,906)	(26,358)

NET LOSS BEFORE INCOME TAXES			(10,938)	(35,807)

PROVISION FOR INCOME TAXES			-	-

NET LOSS			$ (10,938)	$ (35,807)

BASIC AND DILUTED LOSS PER SHARE			$ (0.00)	$ (0.00)

WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING			116,000,000	116,000,000

The accompanying notes are an integral part of these unaudited financial statements.


BIOETHICS, LTD.
Statements of Cash Flows
(Unaudited)

			For the Three Months Ended
			March 31,
			2017	2016

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss			$ (10,938)	$ (35,807)
Adjustments to reconcile net loss to net cash
used by operating activities:
		Amortization of debt discounts	-	25,000
		Depreciation	71	-
Changes in operating assets and liabilities:
		Prepaid expenses	(4,500)	(5,625)
		Interest receivable	-	(1,858)
		Accounts payable	(2,755)	2,009
		Accrued interest - related party	750	750
		Accrued interest	3,156	2,466

		Net Cash Used by Operating Activities	(14,216)	(13,065)

CASH FLOWS FROM INVESTING ACTIVITIES			-	-

CASH FLOWS FROM FINANCING ACTIVITIES			-	-

DECREASE IN CASH AND CASH EQUIVALENTS			(14,216)	(13,065)

CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD			65,900	24,653

CASH AND CASH EQUIVALENTS AT
END OF PERIOD			$ 51,684	$ 11,588

SUPPLEMENTAL DISCLOSURES:

	Cash paid for interest		$ -	$ -
	Cash paid for income taxes		$ -	$ -

The accompanying notes are an integral part of these unaudited financial statements.

BIOETHICS, LTD.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

THREE MONTHS ENDED MARCH 31, 2017 and 2016

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990. The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of, and at the complete discretion of, the Company’s officers and directors. The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the three months ended March 31, 2017 and 2016 have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2016 audited financial statements. The results of operations for the periods ended March 31, 2017 and 2016 are not necessarily indicative of the operating results for the full year.

NOTE 2 - PREPAID EXPENSES

In January 2017, the Company paid $6,000 in professional service fees to be rendered through August 2017, resulting in an expense of $1,500 during the three months ended March 31, 2017 and a prepaid expense balance of $4,500 at March 31, 2017.

NOTE 3 RELATED PARTY TRANSACTIONS

Management Compensation - During the three months ended March 31, 2017 and 2016, the Company did not pay any compensation to its officers and directors.

Office Space - The Company has not had a need to rent office space. An officer/shareholder of the Company is allowing the Company to use his home as a mailing address, as needed, at no expense to the Company.

Notes Payable - In December 2014, the Company borrowed $25,000 from the majority shareholder pursuant to an unsecured promissory note, which is due on demand and accrues interest at 12% per annum, or $750 per quarter. The note has accrued $6,750 in interest since its inception, of which $6,000 remains payable at March 31, 2017.

NOTE 4 – NOTE RECEIVABLE

On November 16, 2015, the Company paid $50,000 for a secured promissory note. The note bore interest at 10% per annum and was due on or before May 16, 2016. Any amount of principal and interest on the note that was not paid when due was subject to default interest at the rate of 18% per annum until paid in full. The note was secured by 500,000 shares of the borrower’s common stock, and earned $1,858 in interest income during the three months ended March 31, 2016. On August 5, 2016, the Company received payment in full of $54,484 which consisted of $50,000 principal and $4,484 in accrued interest income.

NOTE 5 - NOTE PAYABLE

On June 14, 2016, the Company issued a promissory note in the original principal amount of $35,000 to an unaffiliated lender. The Note is due on June 14, 2017 and carries an interest rate of 8% per annum. Interest expense for the three months ended March 31, 2017 totaled $690, resulting in accrued interest at March 31, 2017 of $2,224.

BIOETHICS, LTD.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

THREE MONTHS ENDED MARCH 31, 2017 and 2016

NOTE 6 - CONVERTIBLE NOTE PAYABLE

On July 25, 2015, the Company issued a promissory note in the original principal amount of $100,000 to an unaffiliated lender. The Note is due on demand at any time after July 31, 2016 and carries an interest rate of 10% per annum. The Note shall be due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $0.25 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $100,000, which was amortized over the life of the promissory note. During the three months ended March 31, 2016, the Company recorded $25,000 as amortization of debt discount on the statements of operations, resulting in an unamortized debt discount of $-0- and net convertible note balance of $100,000 at March 31, 2017 and December 31, 2016. Interest expense for each of the three months ended March 31, 2017 and 2016 totaled $2,466, resulting in accrued interest at March 31, 2017 and December 31, 2016 of $16,822 and $14,356, respectively.

NOTE 7 - GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has incurred losses since its inception and has no on-going operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock or through a possible business combination. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 8 - LOSS PER SHARE

The following data show the amounts used in computing loss per share:


	For the	For the
	Three Months	Three Months
	Ended	Ended
	March 31,	March 31,
	2017	2016

Loss from continuing operations
applicable to common
stockholders (numerator)	$ (10,938)	$ (35,807)

Weighted average number of
common shares outstanding
used in loss per share calculation
during the period (denominator)	116,000,000	116,000,000

Dilutive loss per share was not presented, as the Company had no common share equivalents for all periods presented that would affect the computation of diluted loss per share. In addition, the Company has experienced continuing losses, so inclusion of any common share equivalents would result in an anti-dilutive effect.

NOTE 9 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no additional events to disclose.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion in conjunction with our financial statements, which are included elsewhere in this report. The following information contains forward-looking statements. (See “Forward-Looking Statements” below and “Risk Factors.”)

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements reflect the Company’s views with respect to future events based upon information available to it at this time. These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from these statements. These uncertainties and other factors include, but are not limited to the risk factors described herein under the caption “Risk Factors.” The words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, changes in assumptions, future events or otherwise.

General

The Company is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the Company.

The Report of Independent Registered Public Accounting Firm on the Company’s 2016 audited financial statements addresses an uncertainty about the Company’s ability to continue as a going concern, indicating that the Company has incurred losses since its inception and has no on-going operations. The report further indicates that these factors raise substantial doubt about the Company’s ability to continue as a going concern. At March 31, 2017, the Company had a working capital deficit of $132,298 and an accumulated deficit since inception of $632,414. The Company incurred net losses of $10,938 and $35,807 for the three months ended March 31, 2017 and 2016, respectively. The Company has not entered into any agreements or arrangements for the provision of additional debt or equity financing and there can be no assurance that it will be able to obtain the additional debt or equity capital required to continue its operations.

The Three Months ended March 31, 2017 compared to March 31, 2016

The Company did not conduct any operations during the three month periods ended March 31, 2017 or 2016. At March 31, 2017, the Company had cash in the amount of $51,684, compared to cash at December 31, 2016 in the amount of $65,900. At March 31, 2017, the Company had total current assets of $56,184, compared to $65,900 at December 31, 2016. At March 31, 2017, the Company had total current liabilities of $188,482, compared to $187,331 at December 31, 2016. The Company had a working capital deficit of $132,298 at March 31, 2017 compared to a working capital deficit of $121,431 at December 31, 2016.

The Company did not generate revenues during the three month periods ending March 31, 2017 or 2016. The Company incurred general and administrative expenses of $7,032 during the three months ended March 31, 2017, compared to $9,449 during the three months ended March 31, 2016. Such expenses consist primarily of legal and accounting fees as well as taxes and annual fees required to maintain the Company’s corporate status.

The Company incurred other expenses and income of $3,906 during the three months ended March 31, 2017 compared to $26,358 during the three months ended March 31, 2016. Total other expenses and income consist of interest expense/income related to the notes payable/receivable due from/to the Company. During the three months ended March 31, 2016, interest expense of $28,216 (including the amortization of debt discount of $25,000) was netted with interest income of $1,858.

The Company incurred a net loss of $10,938 during the three months ended March 31, 2017, compared to a net loss of $35,807 during the three months ended March 31, 2016. The decrease in net loss in 2017 as compared to 2016 is mainly the result of the amortization of debt discount in the amount of $25,000 related to the convertible promissory note which was recorded during the three months ended March 31, 2016.

The Company has never had substantial ongoing operations. As a result, since its inception on July 26, 1990, the Company has an accumulated deficit of $632,414.

Liquidity and Capital Resources

Net cash used by operating activities was $14,216 and $13,065 during the three months ended March 31, 2017 and 2016, respectively.

There were no cash flows from either investing activities or financing activities during the three months ended March 31, 2017 and 2016, respectively.

Since the Company does not generate any revenues from operations, it is dependent on sales of securities, loans, or contributions from its stockholders in order to pay its operating costs. In addition, in the event the Company locates a suitable candidate for potential acquisition, the Company will require additional funds to pay the costs of negotiating and completing the acquisition of such candidate. The Company has not entered into any agreement or arrangement for the provision of any additional funding and no assurances can be given that such funding will be available to the Company on terms acceptable to it or at all.

The Company cannot presently foresee the cash requirements of any business opportunity which may ultimately be acquired by the Company. However, since it is likely that any business it acquires will be involved in active business operations, the Company anticipates that an acquisition will result in increased cash requirements as well as increases in the number of employees of the Company.

Off-Balance Sheet Arrangements

The Company has not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Critical Accounting Policies

Due to the lack of current operations and limited business activities, the Company does not have any accounting policies that it believes are critical to facilitate an investor’s understanding of the Company’s financial and operating status.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not Applicable. The Company is a “smaller reporting company.”

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer/Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”) as of March 31, 2017, the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer/Chief Financial Officer, who is our sole officer and director, concluded that our disclosure controls and procedures as of March 31, 2017 were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended March 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

In connection with an evaluation of the effectiveness of the Company’s internal control over financial reporting as of March 31, 2017, using the COSO framework (1992), our management, with the participation of our Chief Executive Officer/Chief Financial Officer identified a weakness in the Company’s internal control, which arises from the fact that the Company’s principal executive and principal financial officers are the same person, which does not allow for segregation of duties. Our management believes the materiality of this weakness is mitigated by the Company’s status as a shell company with no significant assets or liabilities, no business operations and a limited number of transactions each year, and that the weakness does not have a material effect on the accuracy and completeness of our financial reporting and disclosure as included in this report.

Part II---OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is not a party to any material pending legal proceedings and, to the best of its knowledge; its properties are not the subject of any such proceedings.

Item 1A. Risk Factors.

See the risk factors described in Item 1A of the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Item 6.

Exhibits

The following documents are included as exhibits to this report:

(a)

Exhibits


Exhibit Number	SEC Reference Number	Title of Document	Location

31.1	31	Section 302 Certification of Chief Executive and Chief Financial Officer	This Filing
32.1	32	Section 1350 Certification of Chief Executive and Chief Financial Officer	This Filing
101.INS**		XBRL Instance Document	This Filing
101.SCH**		XBRL Taxonomy Extension Schema	This Filing
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase	This Filing
101.DEF**		XBRL Taxonomy Extension Definition Linkbase	This Filing
101.LAB**		XBRL Taxonomy Extension Label Linkbase	This Filing
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase	This Filing

**XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Bioethics, Ltd.


Date: May 17, 2017	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-31 2 f20170331bioethicsexhibit311.htm Converted by EDGARwiz

Exhibit 31.1

I, Mark A. Scharmann, certify that:

I have reviewed this report on Form 10-Q of Bioethics, Ltd;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



	Bioethics, Ltd.
Date: May 17, 2017	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-32 3 f20170331bioethicsexhibit321.htm Converted by EDGARwiz

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bioethics, Ltd. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Mark A. Scharmann, President, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


	Bioethics, Ltd.


Date: May 17, 2017	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

EX-101.INS 4 bioe-20170331.xml 10-Q 2017-03-31 false BIOETHICS LTD 0000894560 bioe --12-31 116000000 116000000 Smaller Reporting Company No No No 2017 Q1

51684

65900

4500

56184

65900

1298

1369

57482

67269

3436

6191

6000

5250

19046

15890

35000

25000

100000

188482

187331

188482

187331

116000

385414

-632414

-621476

-131000

-120062

57482

67269

7032

9449

7032

9449

-7032

-9449

1858

-3906

-28216

-3906

-26358

-10938

-35807

-10938

-35807

-0.00

116000000

-10938

-35807

25000

-4500

-5625

-1858

-2755

2009

750

3156

2466

-14216

-13065

-14216

-13065

65900

24653

51684

11588

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Organization - Bioethics, Ltd. (the Company) was organized under the laws of the State of Nevada on July 26, 1990.  The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of, and at the complete discretion of, the Companys officers and directors.  The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.   The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the three months ended March 31, 2017 and 2016 have been made.   Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Companys December 31, 2016 audited financial statements.  The results of operations for the periods ended March 31, 2017 and 2016 are not necessarily indicative of the operating results for the full year.

NOTE 2 - PREPAID EXPENSES   In January 2017, the Company paid $6,000 in professional service fees to be rendered through August 2017, resulting in an expense of $1,500 during the three months ended March 31, 2017 and a prepaid expense balance of $4,500 at March 31, 2017.

NOTE 3 RELATED PARTY TRANSACTIONS   Management Compensation - During the three months ended March 31, 2017 and 2016, the Company did not pay any compensation to its officers and directors.   Office Space - The Company has not had a need to rent office space.  An officer/shareholder of the Company is allowing the Company to use his home as a mailing address, as needed, at no expense to the Company.   Notes Payable - In December 2014, the Company borrowed $25,000 from the majority shareholder pursuant to an unsecured promissory note, which is due on demand and accrues interest at 12% per annum, or $750 per quarter.  The note has accrued $6,750 in interest since its inception, of which $6,000 remains payable at March 31, 2017.

NOTE 4 NOTE RECEIVABLE   On November 16, 2015, the Company paid $50,000 for a secured promissory note.  The note bore interest at 10% per annum and was due on or before May 16, 2016.  Any amount of principal and interest on the note that was not paid when due was subject to default interest at the rate of 18% per annum until paid in full.  The note was secured by 500,000 shares of the borrowers common stock, and earned $1,858 in interest income during the three months ended March 31, 2016.  On August 5, 2016, the Company received payment in full of $54,484 which consisted of $50,000 principal and $4,484 in accrued interest income.

NOTE 5 - NOTE PAYABLE   On June 14, 2016, the Company issued a promissory note in the original principal amount of $35,000 to an unaffiliated lender. The Note is due on June 14, 2017 and carries an interest rate of 8% per annum.  Interest expense for the three months ended March 31, 2017 totaled $690, resulting in accrued interest at March 31, 2017 of $2,224.

NOTE 6 - CONVERTIBLE NOTE PAYABLE   On July 25, 2015, the Company issued a promissory note in the original principal amount of $100,000 to an unaffiliated lender. The Note is due on demand at any time after July 31, 2016 and carries an interest rate of 10% per annum. The Note shall be due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $0.25 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $100,000, which was amortized over the life of the promissory note.  During the three months ended March 31, 2016, the Company recorded $25,000 as amortization of debt discount on the statements of operations, resulting in an unamortized debt discount of $-0- and net convertible note balance of $100,000 at March 31, 2017 and December 31, 2016.  Interest expense for each of the three months ended March 31, 2017 and 2016 totaled $2,466, resulting in accrued interest at March 31, 2017 and December 31, 2016 of $16,822 and $14,356, respectively.

NOTE 7 - GOING CONCERN   The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern.  However, the Company has incurred losses since its inception and has no on-going operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock or through a possible business combination.  There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations.  The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 8 - LOSS PER SHARE   The following data show the amounts used in computing loss per share:                                              <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="528" style='width:316.65pt;border-collapse:collapse'> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'> For the </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'> For the </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'> Three Months </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'> Three Months </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'> Ended </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'> Ended </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'> March 31, </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'> March 31, </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 2017 </td> <td width="120" valign="top" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 2016 </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> Loss from continuing operations </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> applicable to common </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> stockholders (numerator) </td> <td width="140" valign="top" style='width:84.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> $           (10,938)  </td> <td width="120" valign="top" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> $      (35,807) </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="140" valign="top" style='width:84.1pt;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> Weighted average number of </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> common shares outstanding </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> used in loss per share calculation </td> <td width="140" valign="top" style='width:84.1pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="120" valign="top" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="268" valign="top" style='width:160.55pt;padding:0in 5.4pt 0in 5.4pt'> during the period (denominator) </td> <td width="140" valign="top" style='width:84.1pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 116,000,000  </td> <td width="120" valign="top" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> 116,000,000 </td> </tr> </table> </div>   Dilutive loss per share was not presented, as the Company had no common share equivalents for all periods presented that would affect the computation of diluted loss per share. In addition, the Company has experienced continuing losses, so inclusion of any common share equivalents would result in an anti-dilutive effect.

NOTE 9 SUBSEQUENT EVENTS   The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no additional events to disclose.

0000894560 2017-01-01 2017-03-31 0000894560 2017-03-31 0000894560 2016-06-30 0000894560 2016-12-31 0000894560 2016-01-01 2016-03-31 0000894560 2016-03-31 0000894560 2015-12-31 iso4217:USD shares iso4217:USD shares EX-101.SCH 5 bioe-20170331.xsd 000010 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Note 3 Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 9 - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000040 - Disclosure - Note 1 Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Note 7 - Going Concern link:presentationLink link:definitionLink link:calculationLink 000050 - Disclosure - Note 2 - Prepaid Expenses link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 8 - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 000000 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 6 - Convertible Note Payable link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 5 - Note Payable link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 4 - Note Receivable link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 bioe-20170331_cal.xml EX-101.DEF 7 bioe-20170331_def.xml EX-101.LAB 8 bioe-20170331_lab.xml Note 6 - Convertible Note Payable TOTAL LIABILITIES TOTAL LIABILITIES Interest receivable Total Operating Expenses Common stock, $0.001 par value; 150,000,000 shares authorized, 116,000,000 shares issued and outstanding Note 7 - Going Concern Note 4 - Note Receivable Note 2 - Prepaid Expenses Changes in operating assets and liabilities: LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Entity Well-known Seasoned Issuer Accounts payable {1} Accounts payable Prepaid expenses {1} Prepaid expenses Total Stockholders' Equity (Deficit) Total Stockholders' Equity (Deficit) Entity Central Index Key Notes Adjustments to reconcile net loss to net cash used by operating activities: WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING NET LOSS BEFORE INCOME TAXES Entity Voluntary Filers Note 5 - Note Payable Note 3 Related Party Transactions TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Total Current Assets Total Current Assets Entity Current Reporting Status OTHER INCOME (EXPENSES) LOSS FROM OPERATIONS FIXED ASSETS, NET Current Fiscal Year End Date Trading Symbol Document and Entity Information: Note 1 Summary of Significant Accounting Policies CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Profit (loss) NET INCOME (LOSS) NET INCOME (LOSS) PROVISION FOR INCOME TAXES Notes payable - related party Prepaid expenses Net Cash Used by Operating Activities Net Cash Used by Operating Activities Interest income Total Current Liabilities Total Current Liabilities Document Type DECREASE IN CASH AND CASH EQUIVALENTS DECREASE IN CASH AND CASH EQUIVALENTS NET REVENUES Additional paid-in capital CURRENT LIABILITIES TOTAL ASSETS TOTAL ASSETS Entity Public Float REVENUES Cash and cash equivalents Document Fiscal Period Focus Accrued interest {1} Accrued interest Depreciation General and administrative Accrued interest Notes payable Accounts payable ASSETS CASH FLOWS FROM OPERATING ACTIVITIES BASIC AND DILUTED LOSS PER SHARE OPERATING EXPENSES Amendment Flag Entity Registrant Name Note 9 - Subsequent Events Amortization of debt discounts Accumulated deficit Convertible notes payable Accrued interest - related party Entity Common Stock, Shares Outstanding Note 8 - Loss Per Share Interest expense Document Fiscal Year Focus Entity Filer Category Document Period End Date Accrued interest - related party {1} Accrued interest - related party Total Other Income (Expenses) STOCKHOLDERS' EQUITY (DEFICIT) CURRENT ASSETS EX-101.PRE 9 bioe-20170331_pre.xml XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - USD ($)	3 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Document and Entity Information:
Entity Registrant Name	BIOETHICS LTD
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Trading Symbol	bioe
Amendment Flag	false
Entity Central Index Key	0000894560
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	116,000,000
Entity Public Float		$ 116,000,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML 11 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 51,684	$ 65,900
Prepaid expenses	4,500
Total Current Assets	56,184	65,900
FIXED ASSETS, NET	1,298	1,369
TOTAL ASSETS	57,482	67,269
CURRENT LIABILITIES
Accounts payable	3,436	6,191
Accrued interest - related party	6,000	5,250
Accrued interest	19,046	15,890
Notes payable	35,000	35,000
Notes payable - related party	25,000	25,000
Convertible notes payable	100,000	100,000
Total Current Liabilities	188,482	187,331
TOTAL LIABILITIES	188,482	187,331
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $0.001 par value; 150,000,000 shares authorized, 116,000,000 shares issued and outstanding	116,000	116,000
Additional paid-in capital	385,414	385,414
Accumulated deficit	(632,414)	(621,476)
Total Stockholders' Equity (Deficit)	(131,000)	(120,062)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 57,482	$ 67,269

XML 12 R3.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	3 Months Ended
Statements of Operations - USD ($)	Mar. 31, 2017	Mar. 31, 2016
OPERATING EXPENSES
General and administrative	$ 7,032	$ 9,449
Total Operating Expenses	7,032	9,449
LOSS FROM OPERATIONS	(7,032)	(9,449)
OTHER INCOME (EXPENSES)
Interest income		1,858
Interest expense	(3,906)	(28,216)
Total Other Income (Expenses)	(3,906)	(26,358)
NET LOSS BEFORE INCOME TAXES	(10,938)	(35,807)
NET INCOME (LOSS)	$ (10,938)	$ (35,807)
BASIC AND DILUTED LOSS PER SHARE	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	116,000,000	116,000,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	3 Months Ended
Statements of Cash Flows - USD ($)	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Profit (loss)	$ (10,938)	$ (35,807)
Adjustments to reconcile net loss to net cash used by operating activities:
Amortization of debt discounts		25,000
Depreciation	71
Changes in operating assets and liabilities:
Prepaid expenses	(4,500)	(5,625)
Interest receivable		(1,858)
Accounts payable	(2,755)	2,009
Accrued interest - related party	750	750
Accrued interest	3,156	2,466
Net Cash Used by Operating Activities	(14,216)	(13,065)
DECREASE IN CASH AND CASH EQUIVALENTS	(14,216)	(13,065)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	65,900	24,653
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 51,684	$ 11,588

XML 14 R5.htm IDEA: XBRL DOCUMENT

Note 1 Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Notes

Note 1 Summary of Significant Accounting Policies

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

XML 15 R6.htm IDEA: XBRL DOCUMENT

Note 2 - Prepaid Expenses

3 Months Ended

Mar. 31, 2017

Notes

Note 2 - Prepaid Expenses

NOTE 2 - PREPAID EXPENSES

XML 16 R7.htm IDEA: XBRL DOCUMENT

Note 3 Related Party Transactions

3 Months Ended

Mar. 31, 2017

Notes

Note 3 Related Party Transactions

NOTE 3 RELATED PARTY TRANSACTIONS

Management Compensation - During the three months ended March 31, 2017 and 2016, the Company did not pay any compensation to its officers and directors.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 17 R8.htm IDEA: XBRL DOCUMENT

Note 4 - Note Receivable

3 Months Ended

Mar. 31, 2017

Notes

Note 4 - Note Receivable

NOTE 4 – NOTE RECEIVABLE

XML 18 R9.htm IDEA: XBRL DOCUMENT

Note 5 - Note Payable

3 Months Ended

Mar. 31, 2017

Notes

Note 5 - Note Payable

NOTE 5 - NOTE PAYABLE

XML 19 R10.htm IDEA: XBRL DOCUMENT

Note 6 - Convertible Note Payable

3 Months Ended

Mar. 31, 2017

Notes

Note 6 - Convertible Note Payable

NOTE 6 - CONVERTIBLE NOTE PAYABLE

XML 20 R11.htm IDEA: XBRL DOCUMENT

Note 7 - Going Concern

3 Months Ended

Mar. 31, 2017

Notes

Note 7 - Going Concern

NOTE 7 - GOING CONCERN

XML 21 R12.htm IDEA: XBRL DOCUMENT

Note 8 - Loss Per Share

3 Months Ended

Mar. 31, 2017

Notes

Note 8 - Loss Per Share

NOTE 8 - LOSS PER SHARE

The following data show the amounts used in computing loss per share:

	For the	For the
	Three Months	Three Months
	Ended	Ended
	March 31,	March 31,
	2017	2016

Loss from continuing operations
applicable to common
stockholders (numerator)	$ (10,938)	$ (35,807)

Weighted average number of
common shares outstanding
used in loss per share calculation
during the period (denominator)	116,000,000	116,000,000

XML 22 R13.htm IDEA: XBRL DOCUMENT

Note 9 - Subsequent Events

3 Months Ended

Mar. 31, 2017

Notes

Note 9 - Subsequent Events

NOTE 9 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no additional events to disclose.

EXCEL 23 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 27 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 7 63 1 false 0 0 false 3 false false R1.htm 000000 - Document - Document and Entity Information Sheet http://bioe/20170331/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000010 - Statement - Balance Sheets Sheet http://bioe/20170331/role/idr_BalanceSheets Balance Sheets Statements 2 false false R3.htm 000020 - Statement - Statements of Operations Sheet http://bioe/20170331/role/idr_StatementsOfOperations Statements of Operations Statements 3 false false R4.htm 000030 - Statement - Statements of Cash Flows Sheet http://bioe/20170331/role/idr_StatementsOfCashFlows Statements of Cash Flows Statements 4 false false R5.htm 000040 - Disclosure - Note 1 Summary of Significant Accounting Policies Sheet http://bioe/20170331/role/idr_DisclosureNote1SummaryOfSignificantAccountingPolicies Note 1 Summary of Significant Accounting Policies Notes 5 false false R6.htm 000050 - Disclosure - Note 2 - Prepaid Expenses Sheet http://bioe/20170331/role/idr_DisclosureNote2PrepaidExpenses Note 2 - Prepaid Expenses Notes 6 false false R7.htm 000060 - Disclosure - Note 3 Related Party Transactions Sheet http://bioe/20170331/role/idr_DisclosureNote3RelatedPartyTransactions Note 3 Related Party Transactions Notes 7 false false R8.htm 000070 - Disclosure - Note 4 - Note Receivable Sheet http://bioe/20170331/role/idr_DisclosureNote4NoteReceivable Note 4 - Note Receivable Notes 8 false false R9.htm 000080 - Disclosure - Note 5 - Note Payable Sheet http://bioe/20170331/role/idr_DisclosureNote5NotePayable Note 5 - Note Payable Notes 9 false false R10.htm 000090 - Disclosure - Note 6 - Convertible Note Payable Sheet http://bioe/20170331/role/idr_DisclosureNote6ConvertibleNotePayable Note 6 - Convertible Note Payable Notes 10 false false R11.htm 000100 - Disclosure - Note 7 - Going Concern Sheet http://bioe/20170331/role/idr_DisclosureNote7GoingConcern Note 7 - Going Concern Notes 11 false false R12.htm 000110 - Disclosure - Note 8 - Loss Per Share Sheet http://bioe/20170331/role/idr_DisclosureNote8LossPerShare Note 8 - Loss Per Share Notes 12 false false R13.htm 000120 - Disclosure - Note 9 - Subsequent Events Sheet http://bioe/20170331/role/idr_DisclosureNote9SubsequentEvents Note 9 - Subsequent Events Notes 13 false false All Reports Book All Reports bioe-20170331.xml bioe-20170331.xsd bioe-20170331_cal.xml bioe-20170331_def.xml bioe-20170331_lab.xml bioe-20170331_pre.xml true true ZIP 29 0001551163-17-000107-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551163-17-000107-xbrl.zip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
&UL4$L! A0#% @ MZ9&Q2@+L^2L@"P 19L !4 ( !4S8 &)I;V4M,C Q-S S @,S%?<')E+GAM;%!+!08 !@ & (H! "F00 ! end